Etoposide addition to in vitro topoisomerase II cleavage assays enhanced DNA-topoisomerase II cleavage complexes within DNA substrates that contained MLL and partner gene sequences near translocation breakpoint sites identified in therapy-related leukemias [38,39]. This evidence concerns the gene KMT2A and leukemia.